购物车
- 全部删除
- 您的购物车当前为空
HHLA2 Protein, Human, Recombinant (hFc & Avi), Biotinylated is expressed in HEK293 Cells. The accession number is Q9UM44-1.
规格 | 价格 | 库存 | 数量 |
---|
生物活性 | Immobilized CD28H/TMIGD2 Protein, Human, Recombinant (hFc) (Cat#TMPY-05440) at 2 μg/mL (100 μL/well) can bind HHLA2 Protein, Human, Recombinant (hFc & Avi), Biotinylated (Cat#TMPY-07139), the EC50 is 200-650 ng/mL. |
产品描述 | HHLA2 Protein, Human, Recombinant (hFc & Avi), Biotinylated is expressed in HEK293 Cells. The accession number is Q9UM44-1. |
蛋白纯度 | ≥ 90% as determined by SDS-PAGE. ≥ 90% as determined by SEC-HPLC. |
分子量 | 65.5 kDa (predicted); 95.6 kDa (reducing contition, due to glycosylation) |
研究背景 | B7H7 gene encodes a protein-ligand found on the surface of monocytes. The encoded protein is thought to regulate cell-mediated immunity by binding to a receptor on T lymphocytes and inhibiting the proliferation of these cells. Alternate splicing results in multiple transcript variants. HERV–H LTR-associating 2 (HHLA2, also called B7H7/B7-H5/B7y)has been recently discovered as the newest member of the B7 family and has 23–33% similarity in amino acid sequence with the other B7 molecules. This ligand is the only B7 family member that is found in humans but not in mice. It is constitutively expressed on the surface of human monocytes and is induced on B cells. HHLA2 binds to its putative receptor(s) on a variety of immune cells including CD4 and CD8 T cells and antigen-presenting cells. Similar to B7-H3, both a T cell coinhibitory role, as well as a costimulatory role, has been reported for this ligand.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.